Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

March 15-16, 2013

Las Vegas, Nevada

Continuing Medical Education


Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum 12.5 of AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 12.5 hours of Category 1 credit for completing this program.

Nurses Accreditation

This program has been approved for 12.41 contact hours by the Oncology Nursing Society (ONS). The Continuing Education file number assigned to this offering is 5110.

This continuing nursing education activity was approved by the Oncology Nursing Society, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Who Should Attend

This educational activity is specifically designed for medical, surgical, and radiation oncologists, oncology nurses, nurse practitioners, physicians' assistants, pharmacists, and other healthcare professionals interested and/or involved in the care of patients with cancer.


Upon completion of this educational activity, participants should be able to:

  • Summarize advances in multidisciplinary care, including prognostic factors, molecular biomarkers, and novel therapeutic options, in diverse patient populations with solid tumors
  • Select optimal therapeutic approaches, based on mutation status and other biomarker predictors, for different tumor types including CRC,  NSCLC, and melanoma
  • Discuss emerging clinical data in the management of breast cancers
  • Identify long-term management and survivorship issues in patients with breast cancer
  • Evaluate new directions in the treatment of gastrointestinal cancers, including CRC, gastric cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, and GIST
  • Choose traditional and novel treatment modalities effectively in patients with head and neck cancers
  • Describe recent advances in the treatment of iodine-refractory thyroid cancers
  • Employ current evidence-based strategies in the management approaches for patients with melanoma and other skin cancers
  • Select the best therapeutic strategy for patients with genitourinary malignancies
  • Outline appropriate therapeutic strategies in different disease settings for patients with gynecologic malignancies
  • Formulate an optimal treatment plan for patients with advanced NSCLC with considerations of biomarker profile, histology, co-morbidities, and emerging agents
  • Assess the risks and limitations, including cardiovascular, gastrointestinal, pulmonary, and dermatologic side effects, of new and emerging targeted therapies with potential to impact patient care in multiple tumor types
  • Recommend patients to appropriate clinical trials based on patient and disease characteristics and potential benefits of the trial